Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 12/2007 | Barosense | Series C | 11.2M |
| 11/2017 | Mavupharma | Series A | 0 |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 12/2017 | Aptinyx | Series B | 70M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 4/2001 | Fast Track | Series C | 0 |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2020 | Inipharm | Series A | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 3/2019 | Scout Bio | Series B | 20M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 12/2007 | PowerVision | Series B | 20M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 7/2008 | CVRx | Series E | 0 |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 6/2008 | EBR Systems | Series C | 35M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 8/2008 | Calibra Medical | Series B | 35M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 6/2005 | Cierra | Funding Round | 21M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 8/2009 | Barosense | Series D | 27M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 6/2003 | Xoft | Series B | 0 |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 4/2008 | Stromedix | Series B | 25M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 2/2021 | Seraxis | Series C | 40M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 9/2021 | HilleVax | Equity | 135M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 3/2006 | PowerVision | Series A | 2M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 2/2007 | Pivot Medical | Series A | 2M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 12/2003 | FlowCardia | Series B | 12M |
| 3/2021 | Amunix | Series B | 117M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 3/2009 | Stemgent | Series B | 14M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 9/2002 | Glaukos | Series A | 10M |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 1/1996 | Corixa | Venture Round | - |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 8/2007 | FlowCardia | Series C | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 1/2005 | PowerVision | Series A | 4.4M |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 3/2007 | Stromedix | Series A | 1M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 5/2016 | Aptinyx | Series A | 0 |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 4/2020 | Dascena | Series B | 50M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 12/2004 | Barosense | Series B | 6.2M |
| 10/2005 | EBR Systems | Series B | 21M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 5/2007 | CVRx | Series D | 65M |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 7/2011 | PowerVision | Series C | 24M |
| 1/1996 | ViroPharma | Funding Round | - |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
